

**Minutes of the June 10, 2016
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical
Services**

Members present

Bill Ladwig; Richard Holm; Dana Darger; Lenny Petrik; Kelley Oehlke; Deb Farver; Mikel Holland

DSS staff present

Mike Jockheck, RPh; Sara Aker, Deputy Director SD Medicaid

Administrative business

The P&T meeting was called to order by D. Darger at 1:00 p.m. The minutes of the March meeting were presented. R. Holm made a motion to approve. B. Ladwig seconded the motion. The motion was approved unanimously.

Prior authorization update and statistics

The committee reviewed the prior authorization (PA) activity for April 2016. There were a total of 3,380 PAs processed in the month of April, with 99.97% of those requests responded to in less than eight hours. There were 2,590 requests (77%) received electronically and 790 requests (23%) received by fax.

Analysis of the top 15 therapeutic classes and drug spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from 01/01/2016 – 03/31/2016. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, insulins, and anticonvulsants, misc. The top 15 therapeutic classes make up 40.14% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 23.36% of total claims. The committee also reviewed SD Medicaid drug spend for 2013 – 2016. The committee asked that information regarding Onfi utilization be provided at the September meeting.

Antibiotic utilization/stewardship

Mike informed the committee that the department is working on a study regarding antibiotic utilization and the prescribers who are writing prescriptions for them. The department asked for guidance in this endeavor. The committee thought that this would be a good topic for educational letters.

Tivorbex second review

The committee reviewed the prior authorization form provided for Tivorbex. There was no public comment. K. Oehlke made a motion to approve the form. D. Farver seconded the motion. The motion was approved unanimously.

Nucala second review

The committee reviewed the prior authorization form provided for Nucala. There was no public comment. R. Holm made a motion to approve the form. M. Holland seconded the motion. The motion was approved unanimously.

Varubi second review

The committee reviewed Varubi clinical information at the March meeting and requested that more information be brought to the June meeting, including Emend utilization. There was no public comment. After review, the committee tabled the topic.

Narcan review

The committee reviewed Narcan nasal spray clinical information. There was no public comment. B. Ladwig made a motion to bring the Evzio PA form back for review (to match CDC guidelines) and to include Narcan nasal spray. D. Farver seconded the motion. The motion was approved unanimously. The form will be brought to the next meeting for review.

Zurampic review

The committee reviewed Zurampic clinical information. There was no public comment. The topic was tabled.

Livalo review

The committee reviewed Livalo clinical information. There was no public comment. The topic was tabled.

Gabapentin review

The committee reviewed gabapentin clinical information. There was no public comment. The committee requested that more information be brought back to the next meeting, including pregabalin information.

NSAID/anti-ulcer combination products review

The committee reviewed NSAID/anti-ulcer combination products clinical information. There was no public comment. The topic was tabled.

Antiprotozoal agents review

The committee reviewed antiprotozoal agents clinical information. There was no public comment. The topic was tabled.

Omega-3 fatty acids review

The committee reviewed omega-3 fatty acids clinical information. There was no public comment. The topic was tabled.

Insulin review

The committee reviewed insulin clinical information. Shawn Hanson, representing Novo Nordisk, spoke regarding Tresiba. The topic was tabled.

Xenazine review

The committee reviewed Xenazine clinical information. There was no public comment. The committee requested a prior authorization form be developed and brought back to the next meeting.

The next meeting is scheduled for September 2, 2016. B. Ladwig made a motion to adjourn the P&T Committee meeting. R. Holm seconded the motion. The motion passed unanimously and the meeting was adjourned.